More Stories

Informist, Friday, Nov. 7, 2025

 

Please click here to read all liners published on this story

--Torrent Pharma: Expect our growth to outperform market
--CONTEXT: Comments by Torrent Pharma mgmt in post-earnings analyst concall
--Torrent Pharma: Impact of GST cut has been minimal due to higher discounts
--Torrent Pharma: Have filed application for Semaglutide launch in Brazil
--Torrent Pharma: Hope to close JB Pharma transaction by Jan
--Torrent Pharma: Looking to launch wave of diabetes drugs in Brazil
--Torrent Pharma: To file 4-5 ANDA for US mkt in FY26, 10 ANDAs in FY27
--Torrent Pharma: H1 capex at INR 2 bln, should be INR 3 bln for FY26
 

 

By Sunil Raghu and Arundathi A R

 

MUMBAI – Torrent Pharmaceuticals Ltd. hopes to close the transaction for the acquisition of J.B. Chemicals & Pharmaceuticals Ltd. by January, its management said at a post-earnings analyst conference call on Friday.

 

Torrent Pharma had signed a pact to acquire a 46.39% stake in J.B. Chemicals for INR 119.17 billion in June. The company has made an open offer to shareholders of J.B. Chemicals to acquire an additional 26% stake at INR 1,639.18 per share, a 3.7% discount to the stock's Friday closing price of INR 1,702.90. The open offer will open on Nov. 18 and close on Dec. 1. Torrent Pharma has already received the necessary approvals to buy the controlling stake in J.B. Chemicals from Kohlberg Kravis Roberts & Co. Inc. 

 

Torrent Pharma reported a 30.5% on-year increase in its consolidated net profit to INR 5.9 billion during the Jul-Sept quarter, against the Street's estimate of INR 6.0 billion. Its sales grew 14.3% on year to over INR 33 billion in the September quarter, but fell short of the Street's estimate of INR 32.1 billion.

 

The management said the company has invested INR 2 billion in capital expenditure in the first half of the current financial year and expects INR 3 billion in capital expenditure in FY26. The company intends to invest INR 2-3 billion every year over the coming three years, the management said.

 

Torrent Pharma's Indian business reported revenue of INR 18.2 billion in the September quarter, up 12% year on year, higher than the 8% growth seen by other players in the Indian pharmaceuticals market. Torrent Pharma's chronic business grew at 13%, higher than the 11% industry growth.

 

The company, which has 15 brands with sales of over INR 1 billion each, has increased the strength of its field force to 6,800 at the end of Sept. 30 and plans to increase it to 7,000 by the end of the current financial year. Despite the minimal impact of the goods and services tax cut, owing to higher prevailing discounts during the festive season, Torrent expects to continue and outperform its peers in the market.

 

Talking about the US market, the company's second-biggest revenue earner at INR 3.37 billion in the September quarter, the management said it plans to file at least 4-5 abbreviated new drug applications before the US drug regulator in the current financial year. It plans to file 10 abbreviated new drug applications in FY27 and 15 in FY28. The company has hardly had any new launches in the US markets in a long time. "We think that because of this slightly prolonged period of no launches, we're in this position right now. And given the nature of the business in the US and filing duration and approval, uncertainty, your investments generally would take a minimum of 3-5 years to show a reasonable kind of improvement in profitability," the management said.

 

The company also has a sizeable presence in Brazil, where the revenues grew 21% on year to INR 3.18 billion in the September quarter. The company said it has already filed an application to launch the anti-diabetes and anti-obesity drug Semaglutide in Brazil. It also plans to launch the drug in Indian markets and be among the first group of drug companies to do so. The company's management said it plans to launch a "wave" of anti-diabetes drugs in the Brazilian market.

 

Friday, the company's shares closed 0.8% higher at INR 3,580 on the National Stock Exchange.

End

 

Edited by Saji George Titus

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.